PHARMACY

Senate moves to exempt pharmacies from ‘Red Flags’ credit reporting rule

BY Jim Frederick

ALEXANDRIA, Va. — Independent pharmacists are hailing a move in Congress to exempt pharmacies from burdensome accounting requirements imposed by the Federal Trade Commission.

The U.S. Senate on Tuesday night voted to approve bipartisan legislation that removes community pharmacies and other small businesses from new requirements by the FTC and six other federal agencies regarding the use of credit and debit cards. The so-called “Red Flags” rule, geared toward financial institutions and other creditors, require such entities to develop and implement identity theft prevention and detection programs, and is scheduled to take effect Dec. 31.

The National Community Pharmacists Association today hailed the Senate’s move, long sought by independent pharmacists.

Senators Mark Begich, D-Alaska, and John Thune, R-S.D., authored bipartisan legislation (S. 3987) earlier this year – with the support of Senators Chris Dodd, D-Conn.; Richard Shelby, R-Ala.; and the FTC – to exempt many small businesses from the new rule.

“We commend Sens. Begich, Dodd, Shelby and Thune for their hard work to ensure that reasonable consumer protections can go forward without unduly burdening pharmacists and other providers with unnecessary, time-consuming requirements,” said NCPA EVP and CEO Kathleen Jaeger.

Dodd was quoted by the Congressional Record saying that the legislation “makes clear” that pharmacists and “other types of healthcare providers and other service providers will no longer be classified as ‘creditors’ for the purposes of the Red Flags Rule just because they do not receive payment in full from their clients at the time they provide their services, when they don’t offer or maintain accounts that pose a reasonably foreseeable risk of identity theft.”

In regards to the House vote, the NCPA leader said, “Community pharmacists appreciate passage of this bipartisan, bicameral legislative solution exempting pharmacies and other small businesses from the onerous FTC Red Flags rule, which is intended for financial institutions. Thanks to the House… community pharmacists can continue providing expert medication counseling and other services without an additional regulatory burden.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Humana Pharmacy Solutions receives URAC accreditation

BY Allison Cerra

LOUISVILLE, Ky. — Humana’s pharmacy benefit management business has been awarded pharmacy benefit management accreditation from a nonprofit healthcare accrediting organization.

Humana Pharmacy Solutions was awarded full pharmacy benefit management accreditation by URAC. URAC standards require companies to demonstrate their commitment to quality and safety.

"Humana is honored to receive PBM accreditation from URAC," said William Fleming, Humana Pharmacy Solutions VP. "It’s exciting to us to be recognized in our industry for providing outstanding services. The accreditation renewal also underscores the quality of our work with Humana members, customers, clients, payers and healthcare providers by confirming our compliance with national standards for PBM services."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Endo completes Qualitest acquisition

BY Alaric DeArment

CHADDS FORD, Pa. — Endo Pharmaceuticals has finished its acquisition of Qualitest Pharmaceuticals for $1.2 billion, Endo said Wednesday.

Endo had agreed to buy Qualitest, a privately owned manufacturer of generic drugs, on Dec. 28.

“This acquisition marks another milestone in the transformation of Endo and accelerates our stated strategy of building a diversified healthcare company, better able to respond to the changing economics that drive the U.S. healthcare environment,” Endo president and CEO David Holveck said. “We believe this transaction provides Endo with an enhanced competitive position and critical mass in the generics market, further diversifying our business lines and product offerings and enhancing our portfolio of pain management products.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?